Ph I Study of NBTXR3 With Intensity Modulated Radiation Therapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
Phase of Trial: Phase I/II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs NBTXR 3 (Primary) ; NBTXR 3 (Primary)
- Indications Orofacial cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Nanobiotix
- 06 Jun 2017 Interim results (n=11) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2017 According to a Nanobiotix media release, an immulogical biomarkers analysis will be included in this study.
- 05 Jun 2017 According to a Nanobiotix media release, company is filing a protocol amendment for a dose expansion cohort of 44 additional patients and also plans to expand this study in the US.